These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 180727)

  • 1. Poliovirus antibody differentiation. Methods and application for strain specific diagnosis in complications after oral vaccination.
    Kuwert E; Höher PG; Thraenhart O
    Zentralbl Bakteriol Orig A; 1976 Apr; 234(3):407-12. PubMed ID: 180727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of poliovirus neutralizing antibodies. A seroepidemiologic survey of vaccinated and unvaccinated women of fertile age.
    Moschen ME; Farisano G; Bonello C; Benussi G; Barbone F; Gasparini V; Trivello R
    Boll Ist Sieroter Milan; 1987; 66(2):97-100. PubMed ID: 2822063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immune response of the rabbit to virulent and attenuated strains of type 1 poliovirus.
    Gaudin OG; Viac J; Thouvenot D; Sohier R
    Bull World Health Organ; 1974; 50(6):479-5. PubMed ID: 4376464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of poliovirus neutralizing antibodies eight years after immunization with live, attenuated-virus vaccine.
    Rousseau WE; Noble GR; Tegtmeier GE; Jordan MC; Chin TD
    N Engl J Med; 1973 Dec; 289(25):1357-9. PubMed ID: 4356637
    [No Abstract]   [Full Text] [Related]  

  • 5. [Neutralizing antibodies in the sera of persons vaccinated with intradermal poliovirus vaccine].
    Jarzabek Z; Kańtoch M
    Przegl Epidemiol; 1984; 38(3):323-6. PubMed ID: 6098935
    [No Abstract]   [Full Text] [Related]  

  • 6. [Levels of specific antibodies against poliomyelitis virus and degree of immune protection in Umbria population].
    Stagni G; Merletti L; De Rosa F
    Boll Ist Sieroter Milan; 1979 Jul; 58(3):210-5. PubMed ID: 229884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of efficacy of a live oral poliovirus vaccine for virulent Sabin-like poliovirus 1 strains in Japan.
    Iwai M; Nakayama T; Matsuura K; Hasegawa S; Ando S; Obara M; Nagai Y; Yoshida H; Horie H
    Acta Virol; 2006; 50(2):139-43. PubMed ID: 16808333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization against poliomyelitis: risk/benefit/cost in a changing context.
    Salk J
    Dev Biol Stand; 1979; 43():151-7. PubMed ID: 230106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan.
    Iwai M; Takizawa T; Nakayama T; Matsuura K; Yoshida H; Hasegawa S; Obara M; Horimoto E; Kurata T; Horie H
    Scand J Infect Dis; 2008; 40(3):247-53. PubMed ID: 17907043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Poliomyelitis in New Caledonia: epidemiological data, post-vaccinal seroconversion, prophylactic strategy].
    Louis JP; Panon G; Le Gonidec G
    Med Trop (Mars); 1985; 45(3):223-33. PubMed ID: 2999557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign.
    Stenvik M; Hovi L; Siimes MA; Roivainen M; Hovi T
    Pediatr Infect Dis J; 1987 Dec; 6(12):1106-10. PubMed ID: 2829105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poliovirus antibodies in age groups: an assessment of obligatory vaccination in Belgium.
    Lamy ME; Cornu C; Desmyter J
    Dev Biol Stand; 1979; 43():207-13. PubMed ID: 230111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
    Abbink F; Buisman AM; Doornbos G; Woldman J; Kimman TG; Conyn-van Spaendonck MA
    J Infect Dis; 2005 Mar; 191(6):990-9. PubMed ID: 15717277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel.
    Swartz TA; Green MS; Handscher R; Sofer D; Cohen-Dar M; Shohat T; Habib S; Barak E; Dror Z; Somekh E; Peled-Leviathan T; Yulzari R; Libling A; Mendelson E; Shulman LM
    Vaccine; 2008 Feb; 26(8):1083-90. PubMed ID: 18241962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poliomyelitis vaccines in Belgium: 20 years of experience.
    Andre FE
    Dev Biol Stand; 1979; 43():187-93. PubMed ID: 230109
    [No Abstract]   [Full Text] [Related]  

  • 18. Polio antibody outfit of newborns and infants born after 20 years of mass vaccination with live poliovaccine.
    Koza J; Matyásová I; Danes L; Skovránek V; Havelková M
    J Hyg Epidemiol Microbiol Immunol; 1984; 28(1):25-32. PubMed ID: 6325534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of vaccination with inactivated poliomyelitis vaccines in Iceland.
    Gudnadóttir M
    Dev Biol Stand; 1981; 47():257-9. PubMed ID: 7227654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
    Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
    J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.